메뉴 건너뛰기




Volumn 26, Issue 3, 2006, Pages 265-273

Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases

Author keywords

Immunoglobulin therapy; Intravenous; Primary immune deficiency diseases; Safety and efficacy; Subcutaneous

Indexed keywords

IMMUNOGLOBULIN; VIVAGLOBIN;

EID: 33745145825     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-006-9021-7     Document Type: Article
Times cited : (234)

References (28)
  • 1
    • 0000419304 scopus 로고
    • Agammaglobulinemia
    • Bruton OC: Agammaglobulinemia. Pediatrics 9:722-728, 1952.
    • (1952) Pediatrics , vol.9 , pp. 722-728
    • Bruton, O.C.1
  • 2
    • 33745139749 scopus 로고    scopus 로고
    • Comparison of the efficacy and safety of immunoglobulin given subcutaneously versus intravenous immunoglobulin in the prevention of infection in patients with primary antibody deficiency syndromes
    • Björkander J, Chapel H, Spickett G: Comparison of the efficacy and safety of immunoglobulin given subcutaneously versus intravenous immunoglobulin in the prevention of infection in patients with primary antibody deficiency syndromes. Mol Immunol 35:11-12, 1998.
    • (1998) Mol Immunol , vol.35 , pp. 11-12
    • Björkander, J.1    Chapel, H.2    Spickett, G.3
  • 4
    • 0022444537 scopus 로고
    • Corticosteroids for prevention of adverse reactions to intravenous immune globulin infusions, in hypogammaglobulinemic patients
    • Lederman H, Roifman C, Lavi S, Gelfand E: Corticosteroids for prevention of adverse reactions to intravenous immune globulin infusions, in hypogammaglobulinemic patients. Am J Med 81:443-446, 1986.
    • (1986) Am J Med , vol.81 , pp. 443-446
    • Lederman, H.1    Roifman, C.2    Lavi, S.3    Gelfand, E.4
  • 5
    • 0029071060 scopus 로고
    • Recommendations for off-label use of intravenously administered immunoglobulin preparations
    • University Hospital Consortium Expert Panel for Off-Label Use of Polyvalent Intravenously Administered Immunoglobulin Preparations
    • Ratko TA, Burnett DA, Foulke GE, Matuszewski KA, Sacher RA: Recommendations for off-label use of intravenously administered immunoglobulin preparations. University Hospital Consortium Expert Panel for Off-Label Use of Polyvalent Intravenously Administered Immunoglobulin Preparations. JAMA 273:1865-1870, 1995.
    • (1995) JAMA , vol.273 , pp. 1865-1870
    • Ratko, T.A.1    Burnett, D.A.2    Foulke, G.E.3    Matuszewski, K.A.4    Sacher, R.A.5
  • 7
    • 0029819741 scopus 로고    scopus 로고
    • Complications of intravenous immune globulin treatment in neurologic disease
    • Brannagan TH, 3rd, Nagle KJ, Lange DJ, Rowland LP: Complications of intravenous immune globulin treatment in neurologic disease. Neurology 47:674-677, 1996.
    • (1996) Neurology , vol.47 , pp. 674-677
    • Brannagan III, T.H.1    Nagle, K.J.2    Lange, D.J.3    Rowland, L.P.4
  • 9
    • 0018825013 scopus 로고
    • Immunoglobulin replacement therapy by slow subcutaneous infusion
    • Berger M, Cupps TR, Fauci AS: Immunoglobulin replacement therapy by slow subcutaneous infusion. Ann Intern Med 93:55-56, 1980
    • (1980) Ann Intern Med , vol.93 , pp. 55-56
    • Berger, M.1    Cupps, T.R.2    Fauci, A.S.3
  • 10
    • 0034073949 scopus 로고    scopus 로고
    • The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy
    • Chapel HM, Spickett GP, Ericson D, Engl W, Eibl MM, Bjorkander J: The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol 20:94-100, 2000.
    • (2000) J Clin Immunol , vol.20 , pp. 94-100
    • Chapel, H.M.1    Spickett, G.P.2    Ericson, D.3    Engl, W.4    Eibl, M.M.5    Bjorkander, J.6
  • 11
    • 0025738608 scopus 로고
    • Home treatment of hypogammaglobulinaemia with subcutaneous gammaglobulin by rapid infusion
    • Gardulf A, Hammarstrom L, Smith CI: Home treatment of hypogammaglobulinaemia with subcutaneous gammaglobulin by rapid infusion. Lancet 338:162-166, 1991
    • (1991) Lancet , vol.338 , pp. 162-166
    • Gardulf, A.1    Hammarstrom, L.2    Smith, C.I.3
  • 12
    • 0027180544 scopus 로고
    • The life situations of patients with primary antibody deficiency untreated or treated with subcutaneous gammaglobulin infusions
    • Gardulf A, Bjorvell H, Gustafson R, Hammarstrom L, Smith CI: The life situations of patients with primary antibody deficiency untreated or treated with subcutaneous gammaglobulin infusions. Clin Exp Immunol 92:200-204, 1993.
    • (1993) Clin Exp Immunol , vol.92 , pp. 200-204
    • Gardulf, A.1    Bjorvell, H.2    Gustafson, R.3    Hammarstrom, L.4    Smith, C.I.5
  • 13
    • 0029786174 scopus 로고    scopus 로고
    • Subcutaneous administration of immunoglobulins: What are the advantages?
    • Gardulf A, Hammarstrom L: Subcutaneous administration of immunoglobulins: What are the advantages? Clin Immunother 6:108-116, 1996.
    • (1996) Clin Immunother , vol.6 , pp. 108-116
    • Gardulf, A.1    Hammarstrom, L.2
  • 16
    • 30944444864 scopus 로고    scopus 로고
    • Health-related quality of life and treatment satisfaction in north american patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home
    • Nicolay U, Kiessling P, Berger M, Gupta S, Yel L, Roifman CM, Gardulf A, Eichmann F, Haag S, Massion C, Ochs HD: Health-related quality of life and treatment satisfaction in north american patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home. J Clin Immunol 26:65-72, 2006.
    • (2006) J Clin Immunol , vol.26 , pp. 65-72
    • Nicolay, U.1    Kiessling, P.2    Berger, M.3    Gupta, S.4    Yel, L.5    Roifman, C.M.6    Gardulf, A.7    Eichmann, F.8    Haag, S.9    Massion, C.10    Ochs, H.D.11
  • 17
    • 3543141237 scopus 로고    scopus 로고
    • Octagam 5%, an intravenous IgG product, is efficacious and well tolerated in subjects with primary immunodeficiency diseases
    • Ochs HD, Pinciaro PJ: Octagam 5%, an intravenous IgG product, is efficacious and well tolerated in subjects with primary immunodeficiency diseases. J Clin Immunol 24:309-314, 2004.
    • (2004) J Clin Immunol , vol.24 , pp. 309-314
    • Ochs, H.D.1    Pinciaro, P.J.2
  • 18
    • 2942641966 scopus 로고    scopus 로고
    • Subcutaneous immunoglobulin replacement in primary immunodeficiencies
    • Berger M: Subcutaneous immunoglobulin replacement in primary immunodeficiencies. Clin Immunol 112:1-7, 2004.
    • (2004) Clin Immunol , vol.112 , pp. 1-7
    • Berger, M.1
  • 19
    • 0035822661 scopus 로고    scopus 로고
    • The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia. A randomized, double-blind, multicenter crossover trial
    • Eijkhout HW, van Der Meer JW, Kallenberg CG, Weening RS, van Dissel JT, Sanders LA, Strengers PF, Nienhuis H, Schellekens PT: The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia. A randomized, double-blind, multicenter crossover trial. Ann Intern Med 135:165-174, 2001.
    • (2001) Ann Intern Med , vol.135 , pp. 165-174
    • Eijkhout, H.W.1    Van Der Meer, J.W.2    Kallenberg, C.G.3    Weening, R.S.4    Van Dissel, J.T.5    Sanders, L.A.6    Strengers, P.F.7    Nienhuis, H.8    Schellekens, P.T.9
  • 20
    • 33745040276 scopus 로고    scopus 로고
    • Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies - A prospective, multi-national study
    • In press
    • Gardulf A, Nicolay U, Asensio O, Bernatowska E, et al.: Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies - a prospective, multi-national study. J Clin Immunol In press, 2006.
    • (2006) J Clin Immunol
    • Gardulf, A.1    Nicolay, U.2    Asensio, O.3    Bernatowska, E.4
  • 21
    • 0029736668 scopus 로고    scopus 로고
    • Relationship of the dose of intravenous gammaglobulin to the prevention of infections in adults with common variable immunodeficiency
    • Pruzanski W, Sussman G, Dorian W, Van T, Ibanez D, Redelmeier D: Relationship of the dose of intravenous gammaglobulin to the prevention of infections in adults with common variable immunodeficiency. Inflammation 20:353-359, 1996.
    • (1996) Inflammation , vol.20 , pp. 353-359
    • Pruzanski, W.1    Sussman, G.2    Dorian, W.3    Van, T.4    Ibanez, D.5    Redelmeier, D.6
  • 22
    • 0031871760 scopus 로고    scopus 로고
    • Immunoglobulin replacement treatment by rapid subcutaneous infusion
    • Gaspar I, Gerritsen B, Jones A: Immunoglobulin replacement treatment by rapid subcutaneous infusion. Arch Dis Child 79:48-51, 1998.
    • (1998) Arch Dis Child , vol.79 , pp. 48-51
    • Gaspar, I.1    Gerritsen, B.2    Jones, A.3
  • 23
    • 0022626952 scopus 로고
    • Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulinemia. Detection of IgE antibodies to IgA
    • Burks AW, Sampson HA, Buckley RH: Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulinemia. Detection of IgE antibodies to IgA. N Engl J Med 314:560-564, 1986.
    • (1986) N Engl J Med , vol.314 , pp. 560-564
    • Burks, A.W.1    Sampson, H.A.2    Buckley, R.H.3
  • 24
    • 0031802363 scopus 로고    scopus 로고
    • Induction of unresponsiveness against IgA in IgA-deficient patients on subcutaneous immunoglobulin infusion therapy
    • Sundin U, Nava S, Hammarstrom L: Induction of unresponsiveness against IgA in IgA-deficient patients on subcutaneous immunoglobulin infusion therapy. Clin Exp Immunol 112:341-346, 1998.
    • (1998) Clin Exp Immunol , vol.112 , pp. 341-346
    • Sundin, U.1    Nava, S.2    Hammarstrom, L.3
  • 25
    • 0141574289 scopus 로고    scopus 로고
    • Substitution therapy in immunodeficient patients with anti-IgA antibodies or severe adverse reactions to previous immunoglobulin therapy
    • Eijkhout HW, van den Broek PJ, van der Meer JW: Substitution therapy in immunodeficient patients with anti-IgA antibodies or severe adverse reactions to previous immunoglobulin therapy. Neth J Med 61:213-217, 2003.
    • (2003) Neth J Med , vol.61 , pp. 213-217
    • Eijkhout, H.W.1    Van Den Broek, P.J.2    Van Der Meer, J.W.3
  • 26
    • 3442901469 scopus 로고    scopus 로고
    • Safety, efficacy, and pharmacokinetics of Flebogamma 5% [immune globulin intravenous (human)] for replacement therapy in primary immunodeficiency diseases
    • Berger M, Pinciaro PJ: Safety, efficacy, and pharmacokinetics of Flebogamma 5% [immune globulin intravenous (human)] for replacement therapy in primary immunodeficiency diseases. J Clin Immunol 24:389-396, 2004.
    • (2004) J Clin Immunol , vol.24 , pp. 389-396
    • Berger, M.1    Pinciaro, P.J.2
  • 28
    • 0030793979 scopus 로고    scopus 로고
    • Human intravenous immunoglobulin in primary and secondary antibody deficiencies
    • Stiehm ER: Human intravenous immunoglobulin in primary and secondary antibody deficiencies. Pediatr Infect Dis J 16:696-707, 1997.
    • (1997) Pediatr Infect Dis J , vol.16 , pp. 696-707
    • Stiehm, E.R.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.